Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized study assessing efficacy of the phenotype-directed use of mepolizumab reduces the rate of asthma exacerbations in urban children

Next Previous
Trial Profile

A randomized study assessing efficacy of the phenotype-directed use of mepolizumab reduces the rate of asthma exacerbations in urban children

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary) ; Corticosteroids
  • Indications Asthma; Eosinophilia
  • Focus Therapeutic Use

Most Recent Events

  • 27 Feb 2023 Results assessing the efficacy of mepolizumab in urban children with asthma, presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
  • 11 Apr 2022 New trial record
  • 28 Feb 2022 Results of an analysis aiming to identification of specific airway inflammatory pathways can lead to effective personalized treatment with biologics in asthma and insights to mechanisms of action presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top